ANI 制药 ANIP

Nikhil Lalwani, has served as ANI's President and Chief Executive Officer and as a member of the Board since September 2020. Prior to joining ANI, from April 2017 to April 2020, Mr. Lalwani was Chief Executive Officer of the India Rx Business at Cipla Ltd. (NSE: CIPLA) (Cipla), a global pharmaceutical company. In addition, Mr. Lalwani held various additional executive roles at Cipla, including acting as Chief Executive Officer of Cipla USA from April 2017 to April 2020, as Chief Executive Officer of InvaGen, a subsidiary of Cipla, from April 2016 to April 2020, as Head of US Strategy, M&A and Integration, and as Head of Cipla's Global Respiratory business. In these roles, Mr. Lalwani developed and executed multi-year strategic growth plans for key products and facilitated successful acquisitions as Cipla entered the specialty pharmaceutical space. Prior to Cipla, Mr. Lalwani was an Associate Partner with McKinsey & Company, serving pharmaceutical and healthcare companies across the world, and an engineer with Medtronic. Mr. Lalwani holds a B.S. in Electrical Engineering from Georgia Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.

Christopher K. Mutz has been the Company's Senior Vice President, Head of Rare Disease since February 2021. Mr. Mutz has more than 25 years of experience in the pharmaceutical industry, including eight years at Alexion Pharmaceuticals and 10 years at Merck and Co. From May 2019 to January 2021, Mr. Mutz provided consulting services to pharma/biotech companies on pre-launch commercial strategy and life cycle management focused on rare diseases, and provided collaboration and consulting services to multiple early stage companies focused on rare diseases and oncology. From November 2011 to April 2019, Mr. Mutz held various leadership positions in sales and marketing business units at Alexion and led U.S. commercial operations and strategy, which achieved two breakthroughs in ultra-rare enzyme replacement therapies, and led the strategy for the launch of SOLIRIS for the treatment of two rare diseases. While at Merck, from September 2001 to November 2011, Mr. Mutz held various marketing positions, including as leader of the oncology team at Merck's China subsidiary to support marketed products, and was awarded the Merck Division Award for outstanding contribution, and as a Senior Director, U.S. Marketing of TEMODAR, a treatment for certain types of brain tumors. Mr. Mutz holds a B.A. in Biology from the University of Virginia and an M.B.A. from Cornell University.

Stephen P. Carey has been the Company's Senior Vice President, Finance and Chief Financial Officer since December 2020. From May 2016 to December 2020, Mr. Carey served as Vice President, Finance and Chief Financial Officer of the Company, and served as Corporate Secretary of the Company from May 2020 until July 2022. From June 2007 to October 2015, Mr. Carey held various executive financial positions at Par Pharmaceutical Companies, Inc., including Senior Vice President, Controller and Principal Accounting Officer. Prior to that, Mr. Carey held various financial and accounting positions at Schering-Plough Corporation. Mr. Carey has over 30 years of experience as a financial executive, approximately 25 of which are in the pharmaceutical industry. Mr. Carey began his career at PricewaterhouseCoopers. Mr. Carey graduated from Montclair State University with a B.S. in Accounting.

Meredith W. Cook has been the Company's Senior Vice President, General Counsel and Corporate Secretary since July 2022. Prior to joining ANI, Ms. Cook served as Vice President and Associate General Counsel for Amneal Pharmaceuticals, Inc. from March 2020 to July 2022, where she was responsible for corporate and strategic transactions across all business units, with additional responsibilities related to corporate governance, commercial contracts, employment matters, and overall IP strategy, and as Vice President, Transactions from January 2019 to March 2020. Prior to Amneal Pharmaceuticals, Ms. Cook served as Global Legal Head, M&A, Business Development and Strategic Transactions for Dr. Reddy's Laboratories, Inc. She was previously with Morgan, Lewis & Bockius, LLP and Vinson & Elkins, LLP. Ms. Cook earned an A.B. in East Asian Studies from Princeton University and a J.D. from Tulane Law School.

Ori Gutwerg has been the Company's Senior Vice President, Generics since February 2021. He has over 20 years of experience in the pharmaceutical industry. Prior to joining ANI, Mr. Gutwerg was Vice President, Head of US Generics Rx of Taro Pharmaceutical Industries Ltd. from April 2019 to February 2021, where he was responsible for Taro's US Generic Rx business, including developing and executing strategies to meet targets, promoting sales growth, and building the pipeline portfolio. Mr. Gutwerg also held positions with Xiromed US from October 2014 to March 2019, Perrigo Pharmaceuticals from March 2005 to September 2014 and Agis Group from November 2003 to March 2005. Mr. Gutwerg holds a B.S. in Communications and Economics from the Tel Aviv College of Management and an M.B.A. from the Leon Recanati Graduate School of Business Administration, Tel Aviv University.

Thomas J. Haughey, has served as a director since May 2018 and has been Chairman of the Board since October 2025. Mr. Haughey held the role of General Counsel and Secretary at Par Pharmaceutical Companies, Inc. (Par) from 2003 through 2016. In addition to his role as General Counsel, he held various additional executive roles at Par including President from 2011 to 2012 and Chief Administrative Officer from 2012 to 2016. Prior to that, Mr. Haughey held positions at Schering-Plough Corporation, where he was Chief Counsel from 1998 to 2001 and Legal Director from 2001 to 2003. Previously, Mr. Haughey was an attorney at Cadwalader, Wickersham & Taft and a certified public accountant at Arthur Andersen & Co. Since 2016, Mr. Haughey has been an adjunct professor at Passaic County Community College. Mr. Haughey earned a B.S. in accounting at St. John's University and a J.D. at the New York University School of Law.

Chad Gassert has been the Company's Senior Vice President, Corporate Development & Strategy since November 2021. Mr. Gassert most recently served as Chief Executive Officer of Novitium from June 2016, when he co-founded Novitium, until November 2021, when Novitium was acquired by the Company, and currently maintains that role. Prior to co-founding Novitium, Mr. Gassert began his career at Par Pharmaceuticals in 2005, where he led the company's generic business development efforts. Mr. Gassert has more than two decades of experience in the pharmaceutical industry, serving in positions in product development, manufacturing operations, project management, and business development. Mr. Gassert graduated with a B.A. in Nutritional Science from the University of Delaware.

Krista Davis has been the Company's Senior Vice President and Chief Human Resources Officer since September 2022. Ms. Davis brings over 25 years of executive leadership experience in human resources, talent management, and organizational development. Prior to joining ANI, Ms. Davis served as a global Head of People & Organization (P&O) for the Novartis Technical Operations Division from September 2020 to September 2022, where she led P&O for the Global Cell & Gene platforms. From September 2017 to September 2020, Ms. Davis held various other senior executive roles with Novartis supporting the commercial organization. She also sat on the Global P&O divisional leadership team, the Cell & Gene leadership team, and on the US P&O board. Prior to Novartis, Ms. Davis was Global Director, Leadership and Talent Management at A.T. Kearney. She also served previously as VP, Head of HR for North America at Reckitt Benckiser, and in a variety of leadership roles at Catalent Pharma Solutions, Biovail Pharmaceuticals, and Dun & Bradstreet. Ms. Davis earned a B.A. from McGill University and an M.A. in Educational Technology from Concordia University, Montreal, Canada.

Thomas Rowland has been the Company's Senior Vice President, Head of Established Brands since November 2021. From October 2012 until October 2021, Mr. Rowland was the President and Chief Operating Officer of Arbor Pharmaceuticals, a specialty pharmaceuticals company with a portfolio across multiple therapeutic areas. Prior to that, Mr. Rowland was Chief Business Officer at Ventrus Biosciences, a development stage company focused in gastroenterology. Mr. Rowland has more than 30 years of experience in pharmaceutical operations, including leading commercial organizations as large as 650 personnel and revenue up to $500 million. Mr. Rowland has also led development, regulatory, quality and manufacturing functions. Mr. Rowland holds a B.S. in Finance from Metropolitan State University.

Muthusamy Shanmugam, has served as a director and as the Company's Head of Research & Development and Chief Operating Officer of New Jersey Operations since November 2021. Mr. Shanmugam joined the Board in November 2021 in connection with ANI's acquisition of Novitium Pharma LLC (Novitium), where he was the President and Founder. Mr. Shanmugam has over three decades of experience in the pharmaceutical industry, including serving as President of Novitium (now a wholly owned subsidiary of the Company) from 2016 to November 2021. Prior to co-founding Novitium, Mr. Shanmugam also held positions at Par and Novel Laboratories, Inc. Mr. Shanmugam is a director and founder of Nuray Chemicals Private Limited and Sthree Chemicals Private Limited, both located in India and engaged in manufacturing of active pharmaceutical ingredients, and is a director and founder of SS Pharma LLC, which acts as a U.S. agent for sales of active pharmaceutical ingredients. Mr. Shanmugam is also a director and founder of Esjay LLC and Esjay Pharma Private Limited, which provides R&D and facility consulting services and finished dosage manufacturing, and of Scitus Pharma Services Pvt Ltd, a clinical research organization, both located in India. Mr. Shanmugam began his career as a formulation scientist at Kali Laboratories, Inc. Mr. Shanmugam obtained his M.S. in Industrial Pharmacy from the Tamil Nadu Dr. M.G.R. Medical University and is a registered pharmacist in the state of New York.